Acumen Pharmaceuticals (ABOS) EBITDA (2020 - 2026)

Acumen Pharmaceuticals has disclosed EBITDA across 7 years of filings, most recently posting -$32.6 million for Q2 2026.

• In Q2 2026, EBITDA rose 22.02% year-over-year to -$32.6 million; the TTM figure through Jun 2026 stood at -$105.4 million (up 26.78% YoY), while the FY2025 annual figure was -$123.8 million, down 8.61% from the prior year.
• EBITDA came in at -$32.6 million for Q2 2026 at Acumen Pharmaceuticals, down from -$21.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$9.2 million in Q1 2022 to a low of -$41.8 million in Q2 2025.
• Average EBITDA over 5 years is -$22.1 million, with a median of -$19.8 million recorded in 2023.
• Year-over-year, EBITDA tumbled 202.56% in 2022 and jumped 36.36% in 2025.
• Over 5 years, EBITDA stood at -$14.2 million in 2022, then retreated by 29.74% to -$18.5 million in 2023, then plunged by 114.2% to -$39.6 million in 2024, then jumped by 36.36% to -$25.2 million in 2025, then dropped by 29.2% to -$32.6 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$32.6 million in Q2 2026, -$21.1 million in Q1 2026, and -$25.2 million in Q4 2025.